Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64‐week phase 3 study (reSURFACE 1)

Tildrakizumab is a high‐affinity, humanized immunoglobulin G1κ, anti‐interleukin‐23p19 monoclonal antibody recently approved in Japan for treatment of plaque psoriasis. We report results from Japanese patients treated with tildrakizumab in the multinational, randomized, double‐blind, placebo‐control...

Descripción completa

Detalles Bibliográficos
Autores principales: Igarashi, Atsuyuki, Nakagawa, Hidemi, Morita, Akimichi, Okubo, Yukari, Sano, Shigetoshi, Imafuku, Shinichi, Tada, Yayoi, Honma, Masaru, Mendelsohn, Alan M., Kawamura, Masaki, Ohtsuki, Mamitaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247960/
https://www.ncbi.nlm.nih.gov/pubmed/33630387
http://dx.doi.org/10.1111/1346-8138.15789

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247960/
https://www.ncbi.nlm.nih.gov/pubmed/33630387
http://dx.doi.org/10.1111/1346-8138.15789

Ejemplares similares